# Ajit Singh

> Ajit Singh is a Series A investor at Artiman Ventures backing Health Care and Health Diagnostics. See 15 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Artiman Ventures](https://shizune.co/investors/profile/artiman-ventures)
- Location: San Francisco, United States
- Total investments: 15
- Last investment: Jan 2025
- Lead investor: 27%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ajit-singh-5b0b7b1/

Ajit Singh is a Series A investor at Artiman Ventures in San Francisco focused on Health Care and Health Diagnostics. Ajit Singh has 2 current jobs as Partner at Artiman Ventures and Adjunct Professor at Stanford University School of Medicine. Additionally, Ajit Singh has had 2 past jobs including Lead Director at Max Healthcare.Prior to joining Artiman, Ajit was the President and CEO of BioImagene (acquired by Roche), a Digital Pathology company. BeforeBioImagene, Ajit spent nearly twenty years at Siemens in various roles, most recently as the Chief Executive Officer of the Digital Radiology and Medical Informatics business of Siemens Healthcare. Prior roles included President and CEO of the Oncology Care Systems Group, Group Vice President of Siemens e-Health, and Vice President of Siemens Health Services. From 1989 to 1995, he was at Siemens Corporate Research artificial intelligence, robotics, computer vision, and image analysis. During this time, he concurrently served on the faculty at Princeton University.Ajit has a Ph.D. in Computer Science from Columbia University, a master's degree in Computer Engineering from Syracuse University, and a bachelor's degree in Electrical Engineering from Banaras Hindu University, India. He has published two books and numerous refereed articles and holds five patents.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 33% |
| Health Diagnostics | 4 | 27% |
| Biotechnology | 3 | 20% |
| Medical | 2 | 13% |
| Manufacturing | 2 | 13% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 33% |
| Series B | 2 | 13% |
| Funding Round | 2 | 13% |
| Series C | 1 | 7% |
| Series E | 1 | 7% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 33% |
| India | 2 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Harbinger Health | Harbinger Health is a biotechnology company that develops a two-tier testing model for the detection of early cancer with a blood test. The company combines artificial intelligence with insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing low-cost, multi-cancer bloodtests. | $100M | Venture - Series Unknown | Jan 01, 2025 |  |
| Visby Medical | Visby Medical is a diagnostics company that develops PCR-based diagnostic tests for the detection of infectious diseases. The company develops a device platform that aims to redefine the way an illness is tested and treated. They believe that by taking a human-centric, technology-first approach to device development and they can create tools thatare both highly accurate and delightful to use. | $100M | Series E | Mar 01, 2022 |  |
| Visby Medical | Visby Medical is a diagnostics company that develops PCR-based diagnostic tests for the detection of infectious diseases. The company develops a device platform that aims to redefine the way an illness is tested and treated. They believe that by taking a human-centric, technology-first approach to device development and they can create tools thatare both highly accurate and delightful to use. | $100M | Series C | Apr 05, 2019 |  |
| Visby Medical | Visby Medical is a diagnostics company that develops PCR-based diagnostic tests for the detection of infectious diseases. The company develops a device platform that aims to redefine the way an illness is tested and treated. They believe that by taking a human-centric, technology-first approach to device development and they can create tools thatare both highly accurate and delightful to use. | $100.8M | Series C | Apr 05, 2019 |  |
| TeraPore Technologies | TeraPore's cutting edge technology facilitates rapid and efficient purification of biological fluids. Combining uniform pores with large pore densities enables purification of high-value products with fast processing times. Please contact us for more information. | $6M | Series A | Mar 06, 2018 |  |
| CardioDx | CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failures. | $22.5M |  | Jan 05, 2017 |  |
| Visby Medical | Visby Medical is a diagnostics company that develops PCR-based diagnostic tests for the detection of infectious diseases. The company develops a device platform that aims to redefine the way an illness is tested and treated. They believe that by taking a human-centric, technology-first approach to device development and they can create tools thatare both highly accurate and delightful to use. | $6M |  | Dec 01, 2012 |  |
| CardioDx | CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failures. | $58M | Private Equity | Aug 27, 2012 |  |
| CardioDx | CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failures. | $30.5M | Private Equity | Jul 01, 2012 |  |
| Core Diagnostics | Core Diagnostics is a Clinical laboratory focused on Next Generation Diagnostics for disease stratification and therapy selection. We are focused on bringing the most advanced testing techniques and expertise to India. We aim to become the destination for all your high-end diagnostic needs. | $5M | Series A | Jul 01, 2012 |  |

10 of 15 investments shown.

## Co-investors
- [Longitude Capital](https://shizune.co/investors/profile/longitude-capital) — VC Fund, 3 deals together
- [Acadia Woods Partners](https://shizune.co/investors/profile/acadia-woods-partners) — VC Fund, 2 deals together
- [Asset Management Ventures (AMV)](https://shizune.co/investors/profile/asset-management-ventures) — VC Fund, 2 deals together
- [Kleiner Perkins](https://shizune.co/investors/profile/kleiner-perkins-caufield-byers) — VC Fund, 2 deals together
- [Mohr Davidow Ventures](https://shizune.co/investors/profile/mohr-davidow-ventures) — VC Fund, 2 deals together
- [Valo Ventures](https://shizune.co/investors/profile/valo-ventures) — VC Fund, 2 deals together

## About Artiman Ventures

VC Fund · Palo Alto, United States

Artiman is an early-stage venture fund that seeks to invest in entrepreneurs that have the potential to disrupt multi-billion markets. The firm was established in 2000 and is headquartered in Palo Alto, California, United States.

5 contacts available at Artiman Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Ajit Singh | Partner | https://shizune.co/investors/profile/ajit-singh |
| Amit Shah | Founder & Partner | https://shizune.co/investors/profile/amit-shah-2 |
| Ramesh Radhakrishnan | Partner & Managing Director | https://shizune.co/investors/profile/ramesh-radhakrishnan |
| Brian Wilcove | Partner | https://shizune.co/investors/profile/brian-wilcove |
| Mahmood Panjwani | Entrepreneur in Residence | https://shizune.co/investors/profile/mahmood-panjwani |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ajit Singh invest in?

Ajit Singh invests primarily in Health Care, Health Diagnostics and Biotechnology startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ajit Singh last invest?

The most recent investment recorded for Ajit Singh closed in Jan 2025. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co